PT-141 (Bremelanotide): What the Evidence Actually Shows

Start with the fact most compounded-PT-141 marketing quietly steps around: bremelanotide has a real, FDA-approved product, backed by a real, published Phase 3 trial program — and that approval covers exactly one population. Vyleesi (NDA 210557) was approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women⁸, and its own label states plainly that it is "not indicated for the treatment of HSDD in postmenopausal women or in men"⁶. PT-141 is nonetheless widely marketed, off that same molecule, to men — on evidence that, traced back to its source, comes from a different formulation tested and shelved almost two decades ago, plus a still-unreported, early-stage program testing a different product entirely. This article separates what the trial data actually supports from what marketing has stretched it to cover.

What PT-141 actually is

PT-141 is the research and compounding-market name for bremelanotide, a synthetic peptide and melanocortin receptor (MCR) agonist. Its own FDA label describes its binding profile precisely: it "nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R," with MC1R and MC4R most relevant at therapeutic doses⁶. MC4R-expressing neurons sit throughout the central nervous system, concentrated in the medial preoptic area of the hypothalamus, where bremelanotide is understood to trigger presynaptic dopamine release that increases sexual desire — a brain-mediated mechanism, not a local one³. The label itself is honest about the limits of that understanding, stating outright that "the exact mechanism by which VYLEESI improves HSDD remains unknown"⁶.

That mechanism puts bremelanotide in a fundamentally different category from PDE5 inhibitors like sildenafil (Viagra) or tadalafil (Cialis), even though both get marketed under a broad "sexual performance" umbrella. PDE5 inhibitors work peripherally, on vascular smooth muscle, enhancing blood flow into an erection that arousal has already begun — they don't generate desire, and don't work without it. Bremelanotide's proposed mechanism is upstream of that: a central-nervous-system effect on desire itself, independent of the local blood-flow pathway PDE5 inhibitors act on. The two drug classes were never expected to substitute for each other, which is exactly why Palatin's current investigational program for men (covered below) combines bremelanotide with a PDE5 inhibitor rather than testing it as a replacement.

One more detail in that receptor list matters later in this article: MC1R activation on melanocytes drives melanin production. That's not a side note — it's the mechanistic reason bremelanotide's label carries a hyperpigmentation warning at all, and it's a fact about the molecule itself, not about any particular delivery format.

What the Phase 3 RECONNECT trials actually show

Vyleesi's approval rests on two identical, randomized, double-blind, placebo-controlled Phase 3 trials — RECONNECT studies 301 and 302, conducted 2015-2016. Together they randomized 1,267 premenopausal women with acquired, generalized HSDD (1,202 included in the efficacy analysis), who self-administered subcutaneous bremelanotide 1.75 mg as needed, versus placebo, over 24 weeks¹.

The trials measured two co-primary endpoints, and the published results (as differences from placebo) were:

Both co-primary endpoints reached statistical significance in both individual trials and in the integrated analysis¹. Adverse events reported in 10% or more of bremelanotide patients were nausea, flushing, and headache, most described as mild to moderate¹. A 52-week open-label extension followed: of 856 women who completed the core trials, 684 entered the extension and 272 completed all 52 weeks. Within that open-label group — no placebo arm during the extension, so this shows persistence rather than a fresh placebo-controlled result — FSFI-desire domain scores stayed improved 1.25 to 1.30 points from baseline. Treatment-related adverse events in the extension: nausea in 40.4%, flushing in 20.6%, headache in 12.0%, and no new safety signals were reported².

This is a real, adequately powered, peer-reviewed, twice-replicated trial result. It is also specific to one population: premenopausal women diagnosed with HSDD. Nothing about these numbers describes what bremelanotide does in men, in postmenopausal women, or as a general libido or performance enhancer for someone without a HSDD diagnosis — the trials weren't designed to answer those questions and didn't enroll the population to answer them.

What the FDA label's actual warnings say

Vyleesi's label carries three warnings worth reading in the FDA's own words rather than a paraphrase, because compounded-PT-141 marketing routinely understates or omits all three:

Nausea. The label states nausea "was the most commonly reported adverse reaction, reported in 40% of VYLEESI-treated patients, requiring anti-emetic therapy in 13% of VYLEESI-treated patients and leading to premature discontinuation from the trials for 8% of VYLEESI-treated patients"⁷. This is not a rare or mild footnote — four in ten patients on the approved dosing schedule reported it, and it was severe enough to end treatment for close to one in twelve.

Focal hyperpigmentation. In the Phase 3 trials, 1% of patients receiving up to 8 doses a month developed focal hyperpigmentation — dark patches involving the face, gums, or breasts — versus none on placebo. A separate study pushed the dosing schedule harder specifically to characterize this risk: with daily dosing, 38% of patients developed focal hyperpigmentation within 8 days, and among those who continued 8 more consecutive days, an additional 14% developed new pigmentary changes⁷. Patients with dark skin were more likely to develop it, and the label is explicit that resolution "was not confirmed in all patients after discontinuation" — meaning some cases may not fully reverse⁷. This is the direct clinical expression of the MC1R-melanocyte mechanism described above, not an unrelated side effect. The label recommends no more than 8 doses per month and considering discontinuation if hyperpigmentation develops.

Blood pressure and heart rate. "VYLEESI transiently increases blood pressure and reduces heart rate after each dose," with maximal increases of 6 mmHg systolic and 3 mmHg diastolic blood pressure, peaking 2 to 4 hours post-dose, alongside a heart-rate reduction of up to 5 beats per minute — typically returning to baseline within 12 hours⁷. Because of this, Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

None of these three warnings are formulation-specific quirks of the autoinjector. They describe what bremelanotide, the molecule, does in the body — a fact this article returns to below.

Is there real evidence for PT-141 in men?

This is where the gap between what's marketed and what's actually been tested is widest. The honest answer: the evidence for male use is thin, dated, tied to a formulation that was never approved and was ultimately abandoned, and — separately — a currently active but still-unreported research program that tests a different product than what compounding vendors sell.

The human data that exists predates Vyleesi's approval by more than a decade and used an intranasal spray, not the subcutaneous injection the approved product (and most compounded PT-141) uses. A small 2005 randomized crossover trial in 19 men who already responded to PDE5 inhibitors tested 7.5 mg intranasal PT-141 combined with 25 mg sildenafil against sildenafil alone, using RigiScan measurement over 6 hours, and found the combination produced a significantly greater erectile response than sildenafil alone — without isolating how much of that came from PT-141 itself⁵. A larger 2008 randomized, double-blind, placebo-controlled trial tested 342 men with erectile dysfunction who had not responded to sildenafil, giving 10 mg intranasal bremelanotide against placebo: 33.5% of the bremelanotide group reported a positive clinical outcome versus 8.5% on placebo — a real, statistically meaningful signal, but also a trial with more drug-related adverse events in the treated group, in a formulation given at higher, less predictable systemic exposure than an injection⁴.

That intranasal program never reached approval. Multiple industry and secondary sources report that FDA placed a clinical hold on the intranasal bremelanotide program in 2007, after Phase 3 male-ED trials showed dose-dependent blood pressure elevations, and that Palatin discontinued the nasal-spray program by 2008, pivoting to the subcutaneous route that eventually produced Vyleesi — approved over a decade later, for premenopausal women's HSDD, not for the male-ED indication the nasal program had originally targeted¹⁰. (This history is not independently confirmed here against a primary FDA document with a stable citation; it is reported consistently across secondary industry coverage, and stated here as such rather than upgraded to a directly-sourced regulatory finding.)

The current male-focused research is a genuinely different product from either the approved Vyleesi pen or plain compounded PT-141: Palatin's own investor communications describe an early-stage program combining subcutaneous bremelanotide with a PDE5 inhibitor in a single co-formulated injection, aimed specifically at men who don't respond to PDE5i monotherapy alone — not bremelanotide by itself⁹. An open-label, dose-escalation Phase 2 study of roughly 50 patients targeted topline data by the end of 2024; a separate double-blind, placebo-controlled crossover safety study of subcutaneous bremelanotide alone in 49 men (measuring blood-pressure and plasma-exposure safety, not efficacy) completed dosing with results still pending at last report⁹. Public reporting describes Phase 3 recruitment as anticipated for the second half of 2025, with topline results targeted for the first half of 2026 — meaning no completed, published, placebo-controlled efficacy result for this program exists publicly as of this review, and no FDA filing exists for any male indication.

Put plainly: a reader buying compounded PT-141 marketed for male sexual dysfunction is not getting a product with modern, completed, placebo-controlled trial support behind that specific use. What supporting human evidence exists is a small, dated signal from a discontinued nasal formulation, or comes from a still-in-progress program testing a co-formulated product that isn't what's actually being sold.

What this means if you're considering compounded, reconstituted PT-141

Two separate distinctions matter here, and they cut in different directions.

The first is the one our PT-141 reconstitution calculator already covers: Vyleesi ships as a pre-filled autoinjector, never reconstituted by the patient, while compounded PT-141 is sterile lyophilized powder in a vial that the buyer reconstitutes with bacteriostatic water before drawing up a dose. That's a materially different delivery product, with no FDA review of its dose accuracy, sterility, actual concentration, or purity — the calculator does the vial-to-syringe arithmetic on whatever numbers a reader enters, without validating what's actually in the vial.

The second distinction points the other way. Because Vyleesi's warnings — nausea, hyperpigmentation, transient blood pressure and heart rate changes — trace back to bremelanotide's receptor pharmacology rather than to anything specific about the autoinjector, there's no mechanistic reason to expect a reconstituted, compounded version of the same molecule to be exempt from any of them. The MC1R-melanocyte link behind the hyperpigmentation warning, in particular, doesn't depend on delivery format; it's a property of what the molecule does once it's in the body, whichever syringe put it there. A seller offering the powder-vial product with no mention of nausea rates, hyperpigmentation risk, or the blood-pressure contraindication isn't offering a version of the drug that's been shown to lack those effects — it's omitting warnings the approved product's own trial data and label established for the same active ingredient.

Put those two together, and the practical picture for a reader evaluating compounded PT-141 is this: the underlying molecule has real Phase 3 evidence and a real, if narrow, FDA approval — but only for HSDD in premenopausal women, dosed as a self-administered subcutaneous injection with a defined 8-dose-per-month ceiling, prescribed after screening out uncontrolled hypertension and known cardiovascular disease. Evidence for use outside that population, and for a reconstituted-powder product FDA has never reviewed, is a different and considerably weaker case — not because bremelanotide has been shown not to work elsewhere, but because the trials that would show it either haven't been completed, haven't been published, or were run on a formulation that was shelved before it got that far.